Akebia Therapeutics Inc. Stock
Akebia Therapeutics Inc. Stock
Heavy losses for Akebia Therapeutics Inc. today as the stock fell by -€0.062 (-4.860%).
Currently there is a rather positive sentiment for Akebia Therapeutics Inc. with 8 Buy predictions and 3 Sell predictions.
With a target price of 3 € there is potential for a 141.16% increase which would mean more than doubling the current price of 1.24 € for Akebia Therapeutics Inc..
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
B****
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Akebia Therapeutics Inc. | -4.860% | -2.446% | -36.517% | 113.735% | 8.874% | -49.764% | - |
Ardelyx Inc. | -2.390% | -2.116% | -15.296% | 40.514% | 4.048% | -12.204% | - |
Salarius Pharmaceuticals Inc. | -3.170% | 2.315% | -15.000% | -67.971% | -20.360% | -98.187% | -99.994% |
Brainstorm Cell | 1.170% | -1.874% | -1.485% | -81.975% | 114.440% | -80.717% | - |
Comments
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $5.00 to $6.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Show more
Ratings data for AKBA provided by MarketBeat
News
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The